Table 3:

Subgroup Analyses by ANCA Type, Renal Involvement and Induction Treatment Regimen for Relapse, ESRD, and Death

Outcome	Serologic Remission within 180 days HR (95% CI)	Persistently Positive Titer at 180 days
Adjusted HR† for Relapse
PR3-ANCA+	0.52 (0.20 to 1.33)	1.0 (Ref)
MPO-ANCA+	0.62 (0.40 to 0.96)	1.0 (Ref)
Renal Involvement at Baseline	0.64 (0.39 to 1.03)	1.0 (Ref)
RTX or RTX/CYC treated	0.55 (0.33 to 0.92)	1.0 (Ref)
CYC Only treated	0.47 (0.21 to 1.03)	1.0 (Ref)
TPE Treated	0.49 (0.10 to 2.49)	1.0 (Ref)
Adjusted HR† for ESRD or Death (composite)*
PR3-ANCA+	0.77 (0.34 to 1.74)	1.0 (Ref)
MPO-ANCA+	0.86 (0.58 to 1.28)	1.0 (Ref)
Renal Involvement at Baseline	0.91 (0.63 to 1.32)	1.0 (Ref)
RTX or RTX/CYC treated	0.98 (0.61 to 1.59)	1.0 (Ref)
CYC Only treated	0.95 (0.55 to 1.64)	1.0 (Ref)
TPE Treated	0.95 (0.64 to 1.40)	1.0 (Ref)
Adjusted HR† for ESRD*
PR3-ANCA+	0.55 (0.20 to 1.53)	1.0 (Ref)
MPO-ANCA+	1.03 (0.75 to 1.41)	1.0 (Ref)
Renal Involvement at Baseline	1.00 (0.74 to 1.34)	1.0 (Ref)
RTX or RTX/CYC treated	0.80 (0.53 to 1.21)	1.0 (Ref)
CYC Only treated	1.28 (0.87 to 1.90)	1.0 (Ref)
TPE Treated	0.91 (0.58 to 1.44)	1.0 (Ref)
Adjusted HR† for Death
PR3-ANCA+	1.04 (0.35 to 3.14)	1.0 (Ref)
MPO-ANCA+	0.73 (0.41 to 1.31)	1.0 (Ref)
Renal Involvement at Baseline	0.88 (0.49 to 1.57)	1.0 (Ref)
RTX or RTX/CYC treated	1.04 (0.55 to 1.96)	1.0 (Ref)
CYC Only treated	0.73 (0.27 to 1.96)	1.0 (Ref)
TPE Treated	1.18 (0.69 to 2.02)	1.0 (Ref)

^*4 patients with ESRD >300d prior to AAV diagnosis were excluded from analyses of ESRD outcomes

^†adjusted for baseline covariates: age, sex, ANCA type, induction treatment regimen, BVAS/WG, eGFR, and treatment with plasma exchange

ANCA = antineutrophil cytoplasmic antibody, CYC = cyclophosphamide, ESRD = end-stage renal disease, HR = hazard ratio, MPO = myeloperoxidase, PR3 = proteinase-3, RTX = rituximab, TPE = plasma exchange